GAP-486 Clinical Trial

(This study is now closed.)

A Safety and Efficacy Dose-Ranging Study of GAP-486 in Subjects with Nonsustained Ventricular Tachycardia and Acute Ischemia

Purpose:

To learn whether GAP-486 is safe and effective in treating abnormal heartbeats (nonsustained ventricular tachycardia).

Principal Investigator:

Igor Singer MD, FRACP, FACP, FACC, FACA
Executive Medical Director, Cardiovascular Services
Clinical Professor of Medicine and Surgery , University of Illinois

Co-Principal Investigator:

Greg Sowards, MD
Assistant Medical Director, Methodist Emergency Services

For More Information Contact:

Tracy Rennie, MPH, RN
(309) 672-4808
tlrennie@mmci.org

Summary:

GAP-486 is an experimental drug used to treat an abnormal heart rhythm called nonsustained ventricular tachycardia. This abnormal heart rhythm is not considered life-threatening. This study may result in the discovery of a new treatment for a more serious abnormal heart rhythm. About 500 people will take part in this study. Participation in the study will last for approximately 2 weeks. The study has 2 phases -- the inpatient phase, which lasts up to 4 days, and an outpatient phase, which consists of an outpatient visit on day 14. The medication or a placebo will be infused intravenously for up to 24 hours. Study personnel will take blood from a vein approximately 6 times throughout the study. Other requirements include a medical history, a physical examination, cardiac telemetry monitoring and a Holter/ECG cardiac monitor.

This study is now closed. This study is sponsored by Wyeth Pharmaceuticals Co.